Loxo Oncology partners with Roche to develop immunohistochemistry test

Medical Devices Directory Forums Business Partnering Loxo Oncology partners with Roche to develop immunohistochemistry test

This topic contains 0 replies, has 1 voice, and was last updated by  Brückenkopf GmbH 8 months, 3 weeks ago.

Viewing 1 post (of 1 total)
  • Author
    Posts
  • #4249 Reply

    Loxo Oncology announced that the Company has entered into a collaboration agreement with Ventana Medical Systems, Inc., a member of the Roche Group (Roche), to develop and commercialize a pan-TRK immunohistochemistry (IHC) test as a companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib.

    Loxo Oncology and Roche will utilize an investigational assay piloted by Loxo Oncology that will be further developed by Roche using its flagship OptiView DAB detection technology. Initially, the parties will optimize and validate the assay to ensure it is sufficiently robust to withstand clinical and regulatory scrutiny. The parties plan to first globally commercialize an analytical assay and then develop a Class III assay for pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA).

    Share
Viewing 1 post (of 1 total)
Reply To: Loxo Oncology partners with Roche to develop immunohistochemistry test
Your information:




Share